IBRX — Immunitybio Inc

Immunitybio Inc (IBRX) is a biotechnology company listed on NASDAQ. It is led by Richard Gerald Adcock, based in 3530 John Hopkins Court, San Diego, CA, United States, 92121, with about 684 employees. ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.

Latest reported IBRX revenue for 2025-09-30 was $32.1M. Net income was -$67.3M. Revenue was up 21.3% from 2025-06-30 to 2025-09-30. IBRX currently screens at market cap $7.88B.

Use this IBRX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the IBRX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the IBRX SEC filings page. Lician reads the product cache first so this HTML stays unique to Immunitybio Inc even when a live quote feed is slow.